HPV genotypes and associated cervical cytological abnormalities in women from the Pearl River Delta region of Guangdong province, China: A cross-sectional study

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Jing, Lipeng ^a   Zhong, Xingming ^b   Huang, Weihuang ^a   Liu, Yang ^a   Wang, Man ^a   Miao, Zhulin ^b   Zhang, Xiaoping ^c   Zou, Jing ^c   Zheng, Baowen ^d   Chen, Congde ^d   Liang, Xiaoman ^d   Yang, Guang ^a   Jing, Chunxia ^a   Wei, Xiangcai ^a,b  

^a UNIVERSITY OF JINAN   (China)

^b Guangdong Family Planning Special Hospital   (China)

^c BGI SHENZHEN   (China)

^d Guangzhou Kingmed Center for Clinical Laboratory   (China)

Author keywords

Cross sectional study; Cytology; Human papillomavirus; Infection

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CHINA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 6; INTERVIEW; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; QUESTIONNAIRE; RISK FACTOR; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; CERVICAL INTRAEPITHELIAL NEOPLASIA; EPIDEMIOLOGY; GENETICS; GENOTYPE; MASS SPECTROMETRY; MIDDLE AGED; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; VIROLOGY;

VIRUS DNA;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHINA; CROSS-SECTIONAL STUDIES; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; QUESTIONNAIRES; RISK FACTORS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84904086875     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-388     Document Type: Article

References (35)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19.
3. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348(6):518-527.
4. Poljak M. Review of 20 years of HPV research in Slovenia. Acta Dermatovenerol Alp Panonica Adriat 2011, 20(3):99-112.
5. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005, 6(4):204.
6. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009, 10(4):321-322.
7. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjose S, Franceschi S, Clifford GM. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012, 131(10):2349-2359.
8. Bao YP, Li N, Smith JS, Qiao YL. Human papillomavirus type distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer 2008, 18(1):71-79.
9. Kjaer SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T. Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer 2008, 123(8):1864-1870.
10. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjose S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005, 366(9490):991-998.
11. Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC, Ferenczy A, Rohan TE, Villa LL, Franco EL. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003, 95(17):1336-1343.
12. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003, 89(1):101-105.
13. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006, 24(Suppl 3):S3/26-34.
14. Li J, Kang LN, Qiao YL. Review of the cervical cancer disease burden in mainland China. Asian Pac J Cancer Prev 2011, 12(5):1149-1153.
15. Wentzensen N, Schiffman M, Dunn T, Zuna RE, Gold MA, Allen RA, Zhang R, Sherman ME, Wacholder S, Walker J, Wang SS. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer 2009, 125(9):2151-2158.
16. Yi X, Li J, Yu S, Zhang A, Xu J, Yi J, Zou J, Nie X, Huang J, Wang J. A new PCR-based mass spectrometry system for high-risk HPV, part I: methods. Am J Clin Pathol 2011, 136(6):913-919.
17. Qu S, Huang J, Zhao J, Zhao X, Deng H, Yang H, Chen W, Liu L, Zhang L, Gao S. A comparison of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and surface plasmon resonance for genotyping of high-risk human papillomaviruses. Intervirology 2011, 54(6):326-332.
18. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T, Young N. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002, 287(16):2114-2119.
19. Wu RF, Dai M, Qiao YL, Clifford GM, Liu ZH, Arslan A, Li N, Shi JF, Snijders PJ, Meijer CJ, Franceschi S. Human papillomavirus infection in women in Shenzhen City, People's Republic of China, a population typical of recent Chinese urbanisation. Int J Cancer 2007, 121(6):1306-1311.
20. Chen Q, Xie LX, Qing ZR, Li LJ, Luo ZY, Lin M, Zhang SM, Chen WZ, Lin BZ, Lin QL, Li H, Chen WP, Zheng PY, Mao LZ, Chen CY, Yang C, Zhan YZ, Liu XZ, Zheng JK, Yang LY. Epidemiologic characterization of human papillomavirus infection in rural Chaozhou, eastern Guangdong Province of China. PLoS One 2012, 7(2):e32149.
21. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Munoz N. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008, 26(Suppl 10):K1-16.
22. Hou R, Xu C, Zhang S, Wu M, Zhang W. Distribution of human papillomavirus genotype and cervical neoplasia among women with abnormal cytology in Beijing, China. Int J Gynaecol Obstet 2012, 119(3):257-261.
23. Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M, Ferenczy A, Coutlee F, Franco EL. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003, 12(6):485-490.
24. Louvanto K, Rintala MA, Syrjanen KJ, Grenman SE, Syrjanen SM. Genotype-specific persistence of genital human papillomavirus (HPV) infections in women followed for 6 years in the Finnish Family HPV Study. J Infect Dis 2010, 202(3):436-444.
25. Louvanto K, Syrjanen KJ, Rintala MA, Grenman SE, Syrjanen SM. Genotype-specific clearance of genital human papillomavirus (HPV) infections among mothers in the Finnish family HPV study. J Clin Microbiol 2010, 48(8):2665-2671.
26. Schmitt M, Depuydt C, Benoy I, Bogers J, Antoine J, Arbyn M, Pawlita M. Multiple human papillomavirus infections with high viral loads are associated with cervical lesions but do not differentiate grades of cervical abnormalities. J Clin Microbiol 2013, 51(5):1458-1464.
27. Lin M, Yang LY, Li LJ, Wu JR, Peng YP, Luo ZY. Genital human papillomavirus screening by gene chip in Chinese women of Guangdong province. Aust N Z J Obstet Gynaecol 2008, 48(2):189-194.
28. Ye J, Cheng X, Chen X, Ye F, Lu W, Xie X. Prevalence and risk profile of cervical Human papillomavirus infection in Zhejiang Province, southeast China: a population-based study. Virol J 2010, 7:66.
29. Formentin A, Archambault J, Koushik A, Richardson H, Brassard P, Franco EL, Coutlee F. Human papillomavirus type 52 polymorphism and high-grade lesions of the uterine cervix. Int J Cancer 2013, 132(8):1821-1830.
30. Anttila A, Kotaniemi-Talonen L, Leinonen M, Hakama M, Laurila P, Tarkkanen J, Malila N, Nieminen P. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ 2010, 340:c1804.
31. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010, 11(3):249-257.
32. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012, 13(1):78-88.
33. Zhao FH, Lin MJ, Chen F, Hu SY, Zhang R, Belinson JL, Sellors JW, Franceschi S, Qiao YL, Castle PE. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol 2010, 11(12):1160-1171.
34. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, Radberg T, Strander B, Johansson B, Forslund O, Hansson BG, Rylander E, Dillner J. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007, 357(16):1589-1597.
35. Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 2009, 101(23):1612-1623.